SSEP Fluctuations Due to Dexmedetomidine During Posterior Spine Fusion

Study Overview
=================
Brief Summary
-----------------
Intravenous anesthetic agents as far as inhaled agents produce a dose depended increase in latency and decrease in amplitude of SomatoSensory Evoked Potential (SSEP). Dexmetedomidine, a highly selective a2 adrenergic agonist, not only minimizes the anesthetic agents but also the opioids, reducing the analgesic demands. The effect of dexmedetomidine on SSEP has not been elucidated. We aimed to investigate alterations on somatosensory SSEP in adults during posterior spinal fusion surgery before and after Dexmedetomidine administration.

Detailed Description
-----------------
Patients 18-75 years old, ASA (physical status classification system) I-III, scheduled for elective posterior spinal fusion surgery were enrolled in this prospective study. After induction in anesthesia, it was applied SSEP monitoring and a baseline test was performed after 15min (in order to wash out the propofol used for induction). Infusion of Dexmedetomidine was started at a bolus dose of 1mcg/Kg following by 0.7mcg/Kg. Bispectral Index (BIS) monitored the depth of anesthesia and an adequate level (40-50) of anesthesia was maintained by sevoflurane. SSEP were recorded intraoperatively from the tibial nerve (P37) and data were analyzed over that period.

Official Title
-----------------
SSEP Fluctuations Due to Dexmedetomidine During Posterior Spine Fusion

Conditions
-----------------
Spinal Fusion

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with ASA physical status 1-3 Exclusion Criteria: Patients with ASA physical status >3, Body Mass Index (BMI) over 30, indication for rapid sequence induction, any contraindication for receiving b-blocker, Glasgow Coma Scale (GCS) <13, history of drug abuse, neurologic deficit or preoperatively foreseen delayed extubation, preoperative heart rate<45.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Data of SSEPs (amplitude and latency) before dexmedetomidine infusion. | |
| Active Comparator: Dexmedetomidine<br>Data of SSEPs (amplitude and latency) after dexmedetomidine infusion. | Drug: Dexmedetomidine<br>* Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.<br>* Other names: Control-no dexmedetomidine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SSEPs | measurement of SSEPs parameters regarding the baseline. | 10 min after starting infusion of dexmedetomidine | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dexmedetomidine, spinal fusion, SSEP